GeneDx (NASDAQ:WGS) Shares Up 5.4%

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) were up 5.4% on Tuesday . The stock traded as high as $29.63 and last traded at $29.63. Approximately 100,679 shares traded hands during trading, a decline of 74% from the average daily volume of 385,601 shares. The stock had previously closed at $28.10.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on WGS shares. Jefferies Financial Group started coverage on GeneDx in a research note on Monday, June 3rd. They set a “hold” rating and a $21.00 target price on the stock. TD Cowen lifted their price target on GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. BTIG Research lifted their price target on GeneDx from $19.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, June 26th. Finally, The Goldman Sachs Group lifted their price target on GeneDx to $11.00 and gave the stock a “neutral” rating in a research report on Monday, April 15th.

GeneDx Trading Up 6.1 %

The firm has a market cap of $778.64 million, a price-to-earnings ratio of -5.75 and a beta of 2.29. The company has a fifty day moving average price of $23.91 and a 200-day moving average price of $12.79. The company has a current ratio of 3.22, a quick ratio of 2.99 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.35. The business had revenue of $62.42 million during the quarter, compared to analysts’ expectations of $49.80 million. GeneDx had a negative return on equity of 36.23% and a negative net margin of 60.86%. As a group, research analysts expect that GeneDx Holdings Corp. will post -0.92 EPS for the current year.

Insider Activity at GeneDx

In related news, CEO Katherine Stueland sold 6,325 shares of GeneDx stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $11.04, for a total value of $69,828.00. Following the completion of the transaction, the chief executive officer now owns 75,869 shares in the company, valued at approximately $837,593.76. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other GeneDx news, CFO Kevin Feeley sold 2,646 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $28.31, for a total transaction of $74,908.26. Following the completion of the sale, the chief financial officer now directly owns 37,409 shares in the company, valued at approximately $1,059,048.79. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Katherine Stueland sold 6,325 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $11.04, for a total value of $69,828.00. Following the sale, the chief executive officer now owns 75,869 shares of the company’s stock, valued at $837,593.76. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 175,804 shares of company stock worth $3,771,670 and sold 121,505 shares worth $3,211,829. 28.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On GeneDx

Several large investors have recently bought and sold shares of WGS. Thompson Davis & CO. Inc. increased its stake in GeneDx by 99.4% during the 4th quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock worth $55,000 after buying an additional 9,944 shares in the last quarter. Decheng Capital LLC purchased a new stake in shares of GeneDx in the fourth quarter valued at approximately $285,000. PFG Investments LLC purchased a new stake in shares of GeneDx in the first quarter valued at approximately $95,000. Vanguard Group Inc. grew its position in shares of GeneDx by 4.2% in the first quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock valued at $6,460,000 after purchasing an additional 28,678 shares in the last quarter. Finally, Gagnon Advisors LLC grew its position in shares of GeneDx by 41.6% in the first quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock valued at $1,930,000 after purchasing an additional 62,059 shares in the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.